A Prospective, Randomized, Controlled, Crossover Study of Artificial Intelligence-Assisted Multi-Dimensional Staging and Treatment Decision-Making for Hepatocellular Carcinoma

Inclusion Criteria

Inclusion Criteria: * Age \>= 18 years. * Patients prospectively presenting with suspected or newly diagnosed primary hepatocellular carcinoma (HCC) later confirmed by pathology or meeting the China Liver Cancer (CNLC) guidelines. * Complete baseline clinical data acquired during the prospective enrollment period, including complete history of present/past illness, ECOG PS score, comprehensive laboratory tests (liver function, coagulation, tumor markers such as AFP, etc.), and baseline abdominal contrast-enhanced CT. * Patients (or their legal representatives) must provide written informed consent for their clinical data to be used in this trial. Exclusion Criteria: * Patients with secondary (metastatic) liver cancer or concurrent severe malignancies of other systems. * Patients who fail to complete the required baseline imaging or laboratory tests, preventing accurate staging calculation (e.g., missing data for Child-Pugh score). * Patients who have previously received anti-tumor therapies for liver cancer prior to enrollment.